ROIVANT SCIENCES LTD (ROIV)
BMG762791017 - Common Stock
ROIVANT SCIENCES LTD
NASDAQ:ROIV (9/28/2023, 7:11:12 PM)
After market: 11.7 -0.85 (-6.77%)12.55
-0.64 (-4.85%)
Company Profile
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohn’s disease, in addition to various other therapies in various stages of clinical development. The firm advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Company Info
ROIVANT SCIENCES LTD
7th Floor, 50 Broadway
London
P: 442074003347.0
Employees: 904
Website: http://roivant.com/
ROIV News
a day ago - The Motley FoolWhy Immunovant Stock Is Bolting Higher TodayThe company may have best-in-class autoimmune disease therapy under its roof.
2 days ago - Seeking AlphaImmunovant stock rallies for second day, fueled by public offering, drug data (IMVT)Immunovant (IMVT) stock rallied for the second day, fueled by news it was planning to offer $300M of its common shares and positive data for its drug candidate IMVT-1402.
2 days ago - InvezzRoivant stock price outlook: strong pipeline is a catalystRoivant Sciences (NASDAQ: ROIV) stock price surged on Tuesday as investors cheered the latest developments with Immunovant (NASDAQ: IMVT). The shares jumped by more than 20% and retested the year-to-date high of $12.90. They have soared by more than 390% from the lowest point in 2022. Encouraging Immunovant data Roivant Sciences is a biotech company, […]
2 days ago - The Motley FoolWhy Shares of Immunovant Are Soaring on TuesdayImmunovant sees strong potential for an autoimmune disorder therapy.
2 days ago - ChartmillWhich stocks are moving on Tuesday?Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
2 days ago - Seeking AlphaImmunovant drives OmniAb on IMVT-1402 data; argenx slipsOmniAb shares rise while argenx shares decline after Immunovant posts positive early-stage data for its autoimmune drug candidate, IMVT-1402. Read more here.
ROIV Twits
Here you can normally see the latest stock twits on ROIV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
